옵션 체인은 다양한 행사가격과 만기일에 대한 Cerus의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Cerus에 대한 시장 심리를 평가합니다..

Cerus (NASDAQ:CERS) 주식, 옵션 체인

Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cathie Wood in azione: ecco le ultime operazioni di Ark Invest

Equities

News

Markets

ETFs

AMZN

ARKQ

CERS

월요일에 캐시 우드가 이끄는 아크 인베스트가 아마존닷컴(NASDAQ:AMZN)의 주식을 대량 매수하는 중요한 결정을 내렸다. 이는 최근 아마존이 증가하는 에너지 수요를 충족하기 위해 원자력 에너지에 대한 관심을 높이고 있을 가능성이 제기된 가운데 발생한 일이다.

아크 인베스트가 원자력 에너지에 대한 관심 증가로 아마존 주식 395만 달러 규모 매입

Cerus Corp

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells
Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan.

Cerus To Showcase Latest INTERCEPT Blood System Clinical Data At 35th Regional ISBT Congress Being Held May 31 To June 4, 2025, In Milan

France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma

Biotech

General

Cerus Announces Two In-Country Regulatory Approvals For INT200

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) affirms FY2025 sales outlook from $194.00 million-$200.00 million to $194.00 million-$200.00 million vs $221.92 million estimate.

Guidance

Cerus Affirms FY2025 Sales Guidance of $194.00M-$200.00M vs $221.92M Est

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $43.24 million which missed the analyst consensus estimate of $49.62 million by 12.86 percent. This is a 12.70 percent increase over sales of $38.37 million the same period last year.

Earnings

Earnings Misses

Cerus Q1 EPS $(0.04), Inline, Sales $43.24M Miss $49.62M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Cerus to report an earnings per share (EPS) of $-0.05.
The market awaits Cerus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 5.17% drop in the share price the next day.
Here's a look at Cerus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.01</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>15.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746043369_0.png" alt="eps graph" />
<h3>Tracking Cerus's Stock Performance</h3>
Shares of Cerus were trading at $1.36 as of April 29. Over the last 52-week period, shares are down 24.15%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Cerus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Cerus.
The consensus rating for Cerus is Outperform, based on 1 analyst ratings. With an average one-year price target of $4.0, there's a potential 194.12% upside.
<h3>Comparing Ratings with Competitors</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Sanara MedTech, Bioventus and OrthoPediatrics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Sanara MedTech, with an average 1-year price target of $48.5, suggesting a potential 3466.18% upside.</li>
<li>Analysts currently favor an Buy trajectory for Bioventus, with an average 1-year price target of $15.0, suggesting a potential 1002.94% upside.</li>
<li>Analysts currently favor an Buy trajectory for OrthoPediatrics, with an average 1-year price target of $37.83, suggesting a potential 2681.62% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
In the peer analysis summary, key metrics for Sanara MedTech, Bioventus and OrthoPediatrics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerus</td>
<td>Outperform</td>
<td>8.64%</td>
<td>$27.39M</td>
<td>-4.60%</td>
</tr>
<tr>
<td>Sanara MedTech</td>
<td>Buy</td>
<td>48.70%</td>
<td>$24.06M</td>
<td>-3.89%</td>
</tr>
<tr>
<td>Bioventus</td>
<td>Buy</td>
<td>13.45%</td>
<td>$102.66M</td>
<td>-0.11%</td>
</tr>
<tr>
<td>OrthoPediatrics</td>
<td>Buy</td>
<td>40.02%</td>
<td>$35.56M</td>
<td>-4.43%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Cerus ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, Cerus is at the bottom compared to its peers.
<h3>Delving into Cerus's Background</h3>
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
<h3>Cerus: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Cerus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.64% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cerus's net margin excels beyond industry benchmarks, reaching -4.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cerus's ROE excels beyond industry benchmarks, reaching -4.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Cerus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.29% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cerus's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.75, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/CERS/earnings">To track all earnings releases for Cerus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Cerus's Upcoming Earnings Report

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 151.6% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $4.1 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 32.6% to $1.83. The company's market cap stands at $2.6 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares moved upwards by 32.16% to $0.39. The company's market cap stands at $3.3 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock rose 12.66% to $0.23. The company's market cap stands at $6.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock rose 10.2% to $0.22. The market value of their outstanding shares is at $4.7 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 9.92% to $0.69. The market value of their outstanding shares is at $100.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 21.1% to $0.7 during Wednesday's after-market session. The market value of their outstanding shares is at $10.9 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares declined by 16.27% to $32.0. The company's market cap stands at $1.9 billion. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares decreased by 13.73% to $6.85. The company's market cap stands at $1.0 billion. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock decreased by 12.86% to $1.22. The company's market cap stands at $226.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 12.08% to $0.7. The market value of their outstanding shares is at $50.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 11.04% to $1.37. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APVO

BDRX

BDSX

BIAF

CTOR

GNPX

KLTO

OGEN

PTIX

TWST

12 Health Care Stocks Moving In Wednesday's After-Market Session

Cantor Fitzgerald analyst Ross Osborn reiterates Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Overweight and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Cerus, Maintains $4 Price Target

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $56.75 million which beat the analyst consensus estimate of $49.64 million by 14.32 percent. This is a 21.35 percent increase over sales of $46.77 million the same period last year.

Earnings Beats

Cerus Q4 2024 GAAP EPS $(0.01), Inline, Sales $56.75M Beat $49.64M Estimate

AKAM

ALIT

ALRM

ATHM

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BKNG

CARG

CCRD

CDRO

CELH

CENX

CGAU

COKE

COLD

CPRT

CSTM

DAVA

DGICA

DGICB

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance
2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year
Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for full-year 2025.
The Company expects its preliminary full-year 2024 product revenue to be $180.3 million, exceeding the Company's 2024 product revenue guidance range of $177-$179 million. Included in the full-year preliminary 2024 product revenue results were $9.2 million of IFC revenue, representing growth of 42% over 2023 results. These preliminary product revenue results have not been audited and are therefore subject to change.
"We are pleased with our strong performance, which contributed to continued double-digit product revenue growth for the full year 2024, driven by sustained momentum across our INTERCEPT platelet franchise both in the U.S. and internationally and importantly, from our IFC business, which continues to gain momentum," said William "Obi" Greenman, president and chief executive officer of Cerus. "As we look ahead to 2025, we are excited to build on this success through disciplined execution, continued growth in the platelet and IFC franchises, and the advancement of our pipeline, including the planned upcoming LED Illuminator launch in Europe, as well as anticipated further geographic expansion."
The Company expects full-year 2025 product revenue will be in the range of $194-$200 million, of which IFC is expected to be in the range of $12-$15 million. Year-over-year product revenue growth for the first quarter of 2025 is expected to be approximately 10% to 15% over the first quarter of 2024.

Global

Cerus Announces Preliminary 2024 Revenues Of $180.3M, Up 15% From 2023; 2025 Revenue Projected At $194M-$200M, Indicating 8%-11% Growth; IFC Revenue Grows 42% In 2024; 2025 IFC Revenue Predicted Between $12M-$15M; Anticipates LED Illuminator Launch In Europe

WIIM

Cerus shares are trading lower after the company reported mixed Q3 financial results.

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) raises FY2024 sales outlook from $172.00 million-175.00 million to $177.00 million-179.00 million.

Cerus Raises FY2024 Product Revenue Guidance to $177.00M-179.00M  VS Est. 189.86M

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $46.017 million which missed the analyst consensus estimate of $47.335 million by 2.78 percent. This is a 15.70 percent increase over sales of $39.772 million the same period last year.

Cerus Q3 2024 GAAP EPS $(0.02) Beats $(0.03) Estimate, Sales $46.017M Miss $47.335M Estimate

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Cerus to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Cerus's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 14.95% increase in the share price the following trading session.
Here's a look at Cerus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.05</td>
<td>-0.01</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>15.0%</td>
<td>-8.0%</td>
<td>22.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730221292_0_0.png" alt="eps graph" />
<h3>Insights Shared by Analysts on Cerus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Cerus.
Cerus has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $3.0, the consensus suggests a potential 74.42% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of OraSure Technologies, Rockwell Medical and TELA Bio, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, OraSure Technologies is favoring an Neutral trajectory, with an average 1-year price target of $5.0, suggesting a potential 190.7% upside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Rockwell Medical, with an average 1-year price target of $9.0, indicating a potential 423.26% upside.</li>
<li>For TELA Bio, analysts project an Buy trajectory, with an average 1-year price target of $10.4, indicating a potential 504.65% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
In the peer analysis summary, key metrics for OraSure Technologies, Rockwell Medical and TELA Bio are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerus</td>
<td>Buy</td>
<td>16.02%</td>
<td>$24.67M</td>
<td>-11.68%</td>
</tr>
<tr>
<td>OraSure Technologies</td>
<td>Neutral</td>
<td>-36.41%</td>
<td>$24.69M</td>
<td>-0.14%</td>
</tr>
<tr>
<td>Rockwell Medical</td>
<td>Buy</td>
<td>42.88%</td>
<td>$4.55M</td>
<td>1.55%</td>
</tr>
<tr>
<td>TELA Bio</td>
<td>Buy</td>
<td>11.02%</td>
<td>$11.07M</td>
<td>-146.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Cerus ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit. For Return on Equity, Cerus is in the middle compared to its peers.
<h3>Unveiling the Story Behind Cerus</h3>
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
<h3>Breaking Down Cerus's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Cerus displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 16.02%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cerus's net margin excels beyond industry benchmarks, reaching -12.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cerus's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.68%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cerus's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.99, Cerus faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/CERS/earnings">To track all earnings releases for Cerus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cerus's Earnings: A Preview

On Monday, Cathie Wood-led Ark Invest made a significant move by purchasing shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). This comes amidst recent developments suggesting that Amazon may be ramping up its interest in nuclear energy to fuel its growing needs.
The Amazon Trade
Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BAYS: ARKQ) fund purchased 20,883 shares of Amazon, reflecting 0.4951% of the ETF. At the closing price of $189.07 on the same day, the value of the trade amounts to approximately $3.95 million. This move follows a series of recent developments around Amazon&#8217;s potential foray into nuclear energy.
A Benzinga report, in September, revealed that Amazon had <a href="https://www.benzinga.com/markets/equities/24/09/40969515/amazon-going-nuclear-hiring-plans-indicate-company-may-be-eyeing-nuclear-to-meet-energy-needs">reposted a job opening</a> for a Principal Nuclear Engineer in its Data Center Engineering division, raising questions about its long-term energy strategy. Additionally, Amazon announced the expansion of its collaboration with Intel Corp., which has also <a href="https://www.benzinga.com/news/large-cap/24/09/40904271/whats-going-on-with-amazon-stock">positively impacted its stock.</a>
Wood&#8217;s confidence in Amazon has sparked a debate on whether this is a signal of the tech giant&#8217;s impending turnaround or another <a href="https://www.benzinga.com/news/24/10/41247558/cathie-woods-amazon-bet-from-kiss-of-death-to-bold-investment-is-she-right-this-time">high-risk gamble</a>.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Man Who Accidentally Threw Hard Drive Containing 8,000 Bitcoins Worth Half A Billion Dollars In Landfill Sues Local City Council For Not Excavating The Site</a>
Other Key Trades: 
Ark Invest&#8217;s ARKG and ARKK funds bought shares of CRISPR Therapeutics AG (CRSP) and Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>).
ARKQ sold a significant number of shares of Oklo Inc (OKLO) while buying shares of BWX Technologies Inc (BWXT) and 3D Systems Corp ( DDD). Shares of Materialise NV (MTLS) and Markforged Holding Corp (MKFG) were sold by the ARKQ and ARKX funds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41422633/investors-lost-over-95-of-their-wealth-in-this-nvidia-linked-etf-while-jensen-huang-led-chip-gia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Investors Lost Over 95% Of Their Wealth In This Nvidia-Linked ETF While Jensen Huang-Led Chip Giant Gained 220% In The Past Year: Here&#8217;s More</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood's Ark Invest Buys $3.95M Worth Of Amazon Stock Amid Company's Nuclear Moves

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 recording gains on Thursday.
The Dow traded up 0.24% to 43,179.49 while the NASDAQ rose 0.24% to 18,411.77. The S&amp;P 500 also rose, gaining, 0.08% to 5,847.03.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Information technology shares jumped by 0.8% on Thursday.
In trading on Thursday, communication services shares fell by 0.7%.
Top Headline
U.S. crude oil inventories declined by 2.192 million barrels in the week ended Oct. 11, versus estimates of a 2.3 million gain, the EIA said.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares shot up 18% to $2.6650 after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Shares of Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) got a boost, surging 52% to $3.6010 after the company provided updates on the business including its acquisition strategy in traditional markets and enhancing operations through technology and data analytics.</li>
<li>Iridium Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) shares were also up, gaining 12% to $33.97 after the company reported better-than-expected third-quarter revenue results and raised its FY24 OEBITDA guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares dropped 28% to $10.10 after the company announced it expects its third-quarter net income to be significantly degraded due to a reduced level of revenue and resulting loss of operating leverage. Also, the company said it expects that the Longshoremen strike could have negatively impacted unit volumes during the fourth quarter and beyond.</li>
<li>Shares of Cerus Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) were down 18% to $1.4750 after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) was down, falling 16% to $2.75 after the company announced the pricing of an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF).</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $70.19 while gold traded up 0.7% at $2,709.00.
Silver traded down 0.5% to $31.83 on Thursday, while copper fell 0.9% to $4.3270.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.83%, Germany's DAX rose 0.77% and France's CAC 40 climbed 1.22%. Spain's IBEX 35 Index fell 0.77%, while London's FTSE 100 gained 0.67%.
The European Central Bank cut its three key interest rates by 25 bps in October. Annual inflation rate in the Eurozone fell to 1.7% in September versus initial estimates of 1.8% and compared to 2.2% in August.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 1.02%, China's Shanghai Composite Index dipping 1.05% and India's BSE Sensex falling 0.61%.
Economics
<ul>
<li>Industrial production in the U.S. declined 0.3% from a month ago in September.</li>
<li>U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12.</li>
<li>The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.</li>
<li>U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.</li>
<li>Total business inventories increased by 0.3% month-over-month in August.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 43 in October from 41 in the prior month.</li>
<li>U.S. natural-gas stocks increased 76 billion cubic feet during the week ended Oct. 11, compared to market estimates of a 78 billion cubic feet gain.</li>
<li>U.S. crude oil inventories declined by 2.192 million barrels in the week ended Oct. 11, versus estimates of a 2.3 million gain, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41377581/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Trading Ideas

GEVO

IRDM

LCID

NIXX

S&P 5000 Edges Higher; US Crude Oil Inventories Fall

Cerus shares are trading lower after Stifel cut its price target on the stock from $6 to $3.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.5% on Thursday.
The Dow traded up 0.28% to 43,199.12 while the NASDAQ rose 0.53% to 18,464.23. The S&amp;P 500 also rose, gaining, 0.30% to 5,860.00.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Thursday.
In trading on Thursday, real estate shares fell by 0.6%.
Top Headline
U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares shot up 18% to $2.6450 after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Shares of Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) got a boost, surging 116% to $5.12 after the company provided updates on the business including its acquisition strategy in traditional markets and enhancing operations through technology and data analytics.</li>
<li>Iridium Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) shares were also up, gaining 16% to $35.11 after the company reported better-than-expected third-quarter revenue results and raised its FY24 OEBITDA guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares dropped 23% to $10.68 after the company announced it expects its third-quarter net income to be significantly degraded due to a reduced level of revenue and resulting loss of operating leverage. Also, the company said it expects that the Longshoremen strike could have negatively impacted unit volumes during the fourth quarter and beyond.</li>
<li>Shares of Cerus Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) were down 20% to $1.4486 after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) was down, falling 15% to $2.7950 after the company announced the pricing of an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF).</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $70.76 while gold traded up 0.6% at $2,706.20.
Silver traded down 0.2% to $31.91 on Thursday, while copper fell 0.6% to $4.3435.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.8%, Germany's DAX rose 0.60% and France's CAC 40 climbed 1.23%. Spain's IBEX 35 Index fell 0.6%, while London's FTSE 100 gained 0.56%.
The European Central Bank cut its three key interest rates by 25 bps in October. Annual inflation rate in the Eurozone fell to 1.7% in September versus initial estimates of 1.8% and compared to 2.2% in August.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 1.02%, China's Shanghai Composite Index dipping 1.05% and India's BSE Sensex falling 0.61%.
Economics
<ul>
<li>Industrial production in the U.S. declined 0.3% from a month ago in September.</li>
<li>U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12.</li>
<li>The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.</li>
<li>U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise.</li>
<li>Total business inventories increased by 0.3% month-over-month in August.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 43 in October from 41 in the prior month.</li>
<li>U.S. natural-gas stocks increased 76 billion cubic feet during the week ended Oct. 11, compared to market estimates of a 78 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41377581/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Crude Oil Edges Higher; US Retail Sales Top Expectations

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 109.6% to $2.18 during Thursday's regular session. The company's market cap stands at $371.9 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 61.42% to $0.52. The market value of their outstanding shares is at $3.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock increased by 37.97% to $0.46. The company's market cap stands at $13.7 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock rose 36.93% to $1.14. The company's market cap stands at $19.3 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 27.16% to $6.46. The company's market cap stands at $33.6 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 25.11% to $0.46. The market value of their outstanding shares is at $74.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 33.9% to $5.55 during Thursday's regular session. The market value of their outstanding shares is at $80.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 31.23% to $4.45. The company's market cap stands at $4.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) stock fell 19.67% to $2.67. The market value of their outstanding shares is at $107.6 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 18.24% to $1.47. The market value of their outstanding shares is at $272.7 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock fell 15.52% to $0.79. The company's market cap stands at $123.2 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares decreased by 14.99% to $0.67. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

KZIA

MTEM

PIII

QNRX

RENB

SONN

TLPH

TVGN

VSTM

12 Health Care Stocks Moving In Thursday's Intraday Session

Press Releases

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025

Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference

Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

Cerus Corporation Announces First Quarter 2025 Financial Results

Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Comments

Cerus

Cerus (CERS) 옵션

Cerus (NASDAQ:CERS) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌